t(1;3)(p36;p21)

2002-05-01   Jean-Loup Huret 

1.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

Clinics and Pathology

Disease

found in various hematological malignancies: 2 chronic myelogenous leukemia (CML), 1 of which in accelerated phase, 1 myelodysplastic syndrome (MDS) of RAEB type, 2 treatment related MDS, 2 M3- AML (acute myeloid leukemia), 2 acute lymphocytic leukemias (ALL), and 1 treatment related ALL, 3 non Hodgkin lymphoma (NHL), (2 follicular and 1 diffuse large cell NHL) . Five patients had a history of a previous treatment for malignancy (alkylating agent in 3 cases).

Epidemiology

only 13 cases to date; 7 to 87 yr old patients, most patients being in the fifties; sex ratio: 7M/6F

Prognosis

very variable survival, from 25 days to 16 yrs+

Note

according to the variability in the above data, the t(1;3)(p36;p21) is likely to be heterogeneous also at the molecular level.

Bibliography

Pubmed IDLast YearTitleAuthors
118500732002Cytogenetic characterization of diffuse large cell lymphoma using multi-color fluorescence in situ hybridization.Dave BJ et al
112417902001Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18).Horsman DE et al
23108311990Cytogenetic analysis of chimerism and leukemia relapse in chronic myelogenous leukemia patients after T cell-depleted bone marrow transplantation.Offit K et al
119795522002t(1;3)(p36;p21) is a recurring therapy-related translocation.Sato Y et al
897638919963p21 is a recurrent treatment-related breakpoint in myelodysplastic syndrome and acute myeloid leukemia.Shi G et al
78037941995Sequential analysis of 43 patients with non-Hodgkin's lymphoma: clinical correlations with cytogenetic, histologic, immunophenotyping, and molecular studies.Whang-Peng J et al

Citation

Jean-Loup Huret

t(1;3)(p36;p21)

Atlas Genet Cytogenet Oncol Haematol. 2002-05-01

Online version: http://atlasgeneticsoncology.org/haematological/1237/t(1;3)(p36;p21)

External Links